TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04321876

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
Study: NCT01080547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery for Colorectal Cancer
Description: Open surgery for colorectal cancer using conventional methods

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery for Colorectal Cancer
Description: Open surgery for colorectal cancer using conventional methods
Study: NCT04321876

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.

Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
Study: NCT04166968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS)
Description: Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (C-tDCS)
Description: Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (sham-tDCS)
Description: placebo stimulation

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuromotor training
Description: conventional neuromotor treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromotor training
Description: conventional neuromotor treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromotor training
Description: conventional neuromotor treatment
Study: NCT03875495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Genetically modified autologous HSPCs
Study: NCT04043611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physical therapy management
Description: Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA
Description: ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
Study: NCT02194218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine, low dose
Description: 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine, high dose
Description: 100 mg
Study: NCT02536690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
Study: NCT01760681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H- Coil DTMS
Description: 20 daily deep rTMS treatments

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT03700606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: 8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
Study: NCT02680496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
Study: NCT05118607

Intervention type: DEVICE
Group type: OTHER
Intervention: IG1
Description: application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
Study: NCT02323555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paramedic telephone consultation
Study: NCT04544033

Intervention type: DIAGNOSTIC_TEST
Intervention: interleuken 6 level measurment
Description: Detection of IL6 level using ELISA technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: interleuken 6 level measurment
Description: Detection of IL6 level using ELISA technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: interleuken 6 level measurment
Description: Detection of IL6 level using ELISA technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6 Gene-174C detection
Description: The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6 Gene-174C detection
Description: The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6 Gene-174C detection
Description: The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
Study: NCT00504634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1 mg/m\^2 IV On Days 1, 4, 8, and 11.
Study: NCT01338090

Intervention type: DRUG
Intervention: 89Zr-bevacizumab
Description: Intravenous injection 120 MBq

Intervention type: DRUG
Intervention: Everolimus
Description: Oral use, 10 mg per day
Study: NCT01435928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo once daily in the evening with a meal or 30 minutes after eating
Study: NCT03043040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow up
Description: Already described in previous page

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Already described in previous page

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Already described in previous page
Study: NCT02783482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5107
Description: GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
Study: NCT01601743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Running
Description: Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
Study: NCT01868867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: On line tutorial followed by text messaging during treatment and iPad for patient education
Study: NCT03937271

Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine pattern
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.

Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine pattern
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
Study: NCT01906190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
Study: NCT03668457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Patients
Description: Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Patients
Description: Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Psychiatrists
Description: Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Psychiatrists
Description: Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Other: Usual care Usual care for depressive disorder received in mental health units

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Other: Usual care Usual care for depressive disorder received in mental health units

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Other: Usual care Usual care for depressive disorder received in mental health units

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Other: Usual care Usual care for depressive disorder received in mental health units
Study: NCT01545843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep scheduling
Description: 8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep scheduling
Description: 8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine daily for 8 weeks
Study: NCT02284178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced oropharyngeal suction
Description: Deep oropharyngeal suction with catheter every 4 hours

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Oral suction with suction swab every 4 hours
Study: NCT01741012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
Study: NCT00869843

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RF Ablation
Study: NCT01194908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, LBH589, Tamoxifen
Description: Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2
Study: NCT01986725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized care (Intervention I)
Description: During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized care + WOMAN-PRO II program (Intervention II)
Description: This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
Study: NCT01944722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Onclarity™ HPV assay on BD Viper™ LT
Description: The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
Study: NCT03138044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Treatment
Description: This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
Study: NCT02230930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine 0.25% (2.5mg/ml)
Description: Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Massage with a spiky ball
Description: Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone cream 1%
Description: Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous hydrocortisone 10mg
Description: Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
Study: NCT02833428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomedical equipment (Eclipse Nim, Medtronic®)
Description: It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma.
Study: NCT04099433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: Individuals in the interventional arm will undergo daily oral intake of probiotic supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals in the placebo arm will undergo daily oral intake of placebo supplement
Study: NCT03610555

Intervention type: OTHER
Intervention: new patient centered website